Bellicum to be Added to the NASDAQ Biotechnology Index
The NASDAQ Biotechnology Index is designed to track the performance of a
set of securities listed on
About
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151214006297/en/
Source:
Investors:
Bellicum Pharmaceuticals
Alan Musso, CFO,
832-384-1116
amusso@bellicum.com
or
Media:
BMC
Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com